Showing 2776 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with…
-
Press release /Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between…
-
Press release /Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key…
-
Press release /In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were…
-
Press release /Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in…
-
Event /During Eurovision week, the Novartis Campus and the Novartis Pavillon will become a cultural hub, offering free public access, engaging experiences, and inspiring…
-
Event /As Eurovision excitement builds, one of Basel’s most iconic forms of transport is getting a musical makeover. Starting March 31, 2025, the Eurovision tram has hit the…
-
Event /On Saturday, May 17, 2025, as Basel hosts the Eurovision Song Contest, we invite you to Arena plus – an extraordinary public viewing event at St. Jakob-Park,…
-
Event /As part of our Eurovision celebration in Basel, Feel the Beat invites people with and without hearing impairments to come together on one dance floor and experience…
-
Event /As part of our Eurovision partnership and long-standing connection to Basel, Novartis is proud to gift the city the BASEL bench – a lasting symbol of creativity and…